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Summary We aim to assess whether respiratory symptoms are associated with lung
function in young adults, and whether any such relation is similar in those with
asthma, in men and women, and in different countries. Study participants (aged 20–
44 years) were randomly selected from the general population in 35 centres in 15
countries as part of the European Community Respiratory Health Study. In all, 12,541
subjects (47%) completed a respiratory symptoms questionnaire and spirometry,
metacholine challenge and immunoglobulin E tests. Indicators of diagnosed asthma
showed the largest association with airways obstruction (FEV1Fmaximal 1-s forced
expiratory volume/forced vital capacityFFVCo70%), followed by symptoms of
wheezing or shortness of breath, in both genders. Among the 96% of subjects whose
FEV1/FVC ratios were greater or equal to 70%, wheezing or shortness of breath was
associated with lower FEV1 levels (211ml in men and 169ml in women (Po0:01)),
independent of diagnosed asthma, smoking, atopy or bronchial responsiveness. This
association was not explained by a lower FVC. Symptoms of chronic bronchial mucus
hypersecretion (chronic phlegm) were unrelated to both airways obstruction and
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FEV1 levels. Findings were homogeneous across all centres. These results suggest
that lung diseases that cause wheezing are generally associated with impaired lung
function.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Relations between respiratory symptoms and spiro-
metric values remain a contentious issue,1–6
although a priori reasoning dictates that both
symptoms and impaired lung function are different
manifestations of sick lungs. Symptoms of chronic
bronchitis, are very common.1,2 Very few of these
subjects have chronic obstructive pulmonary dis-
eases (COPD),1,2 and the presence of diagnosed
asthma only partly explains these symptoms.3
Typically, when COPD is diagnosed, a long course
of structural and functional changes in the lungs
has already occurred during many decades of life.
When and how symptoms appear during the silent
evolution of FEV1 decline remains uncertain.
4–6 The
part of this phenomenon explained by the presence
of asthma also remains unknown.7–8 Some studies
have shown that children9 and adults10 with asthma
(or its intermediate phenotypes such as immuno-
globulin E (IgE) levels or bronchial responsive-
ness11) have a deficit in the maximum mid
expiratory flow in comparison to subjects without
asthma,9–10 but others have come to different
conclusions.12–13
The study of the relation between symptoms and
lung function in representative samples of the
general population may contribute to the inter-
pretation of respiratory symptoms in an early, ‘sub-
clinical’ stage of COPD (i.e., during youth and the
first decades of adulthood) and, ultimately, to an
understanding of its natural history. One difficulty
in studying these relations is the multiple correla-
tions between symptoms and the complexity of
separating one from another. In a previous study
with multiple respiratory symptoms, we demon-
strated the benefit of using methods of exploratory
factor analysis to group symptoms.14
The European Community Respiratory Health
Survey (ECRHS) is an international study of a
general population sample, aged 20–44 years old,
with cross-sectional information on respiratory
symptoms and lung function, using a standard
procedure in all centres.15 This study permits
investigation of the association between respira-
tory symptoms and lung function in an international
context, with one aim being to describe relation-
ships between symptoms and lung function taking
into account the role of asthma and investigating
both effect modification by sex and homogeneity
between countries.
Subjects and methods
The protocol for the ECRHS has been described
elsewhere.15 Participating centres randomly se-
lected at least 1500 men and 1500 women, aged
20–44 years. A 20% random sample of subjects were
invited to answer a questionnaire on respiratory
symptoms and risk factors, and to take part in
blood tests, skin tests, and assessment of lung
function by spirometry and airway challenge with
methacholine. The overall response rate, with
complete data for all of the questions and
spirometry, was 47% (n ¼ 12; 541). Participants did
not differ in terms of age, rates of smoking, or
symptoms from non-participants.14–16 The Institu-
tional Review Board of the participating centres
approved the study protocol and all participants
gave informed written consent.
The questionnaire on symptoms and medical
history was tested for comprehensibility and
translated into all languages, with back translation
into English.12,13 Baseline forced vital capacity
(FVC) and maximal 1-s forced expiratory volume
(FEV1) were measured following a standard proce-
dure including quality control.15 Subjects were
permitted nine attempts to provide at least two
technically acceptable manoeuvres. Hyper-reactiv-
ity was defined as a 20% or greater fall in FEV1 at
the highest cumulative dose of methacoline, which
was at 1mg or an accumulated dose of 5.117 mmol
of methacoline. Atopy was measured with specific
IgE to common antigens and defined as positive if
levels for any of the allergens were found to be
higher than 0.35 KU/l.15 Smoking definition was
based on the questionnaire.
Descriptive statistics of the association of FEV1
and, separately ratio FEV1/FVC with each symptom
were made. In this analysis all centres were pooled,
and subjects stratified by gender. The association
between each of the symptoms and lung function
indicators was estimated using multilevel (or
hierarchical) models.17 We first assessed the asso-
ciation between symptoms and lung function
adjusted for height and age at individual level per
each of the centres. Next, we assessed whether this
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association has a significant variance component
between centres (heterogeneity of the effect). We
classified subjects with FEV1/FVCo70% as having
airflow obstruction. Among subjects without air-
flow obstruction, FEV1 was treated as a continuous
variable, in ml, which allowed us to assess smaller
changes than if we had treated airflow obstruction
as a dichotomous variable. The measure of associa-
tion was defined as the odds ratio for having a
FEV1/FVC ratio o70% and the linear regression
coefficient for FEV1.
In addition to individual symptoms, a factor
analysis was performed in order to use factors
summarizing groups of symptoms. Factors were
considered latent variables including a combination
of symptoms. All respiratory symptoms in the
ECRHS questionnaire were included in the factor
analysis. Each symptom has a different weight in
each factor according to the observed covariance
among the symptoms. Factors were constructed
using exploratory factor analysis without rota-
tion.18 In a previous analysis, we organized respira-
tory symptoms in the four factors14 shown in Table 3
and entitled as: wheezing/shortness of breath,
cough, hypersecretion and asthma. The latter is
then defined as a combination of questions on
having ever had asthma, attacks of asthma the last
12 months, having been confirmed by a doctor or
having asthma treatment last 12 months. Factors
were scaled in order to range from a minimum of 0
(people not having any of the symptoms in the
factor) to a maximum of 1 (most severe combina-
tion of symptoms). Thus, in the context of this
study, factors incorporate the intensity of symp-
toms, and are not considered a simple dichotomous
variable. The use of factors allowed for separation
of independent associations among a combination
of symptoms and lung function from the other
combinations of symptoms using multivariate mod-
elling including all factors. Given the high correla-
tion among respiratory symptoms, a multivariate
analysis including the observed respiratory symp-
toms instead of the factors would not permit
isolation of the independent association of each
symptom.
Results
Table 1 describes the study participants, grouped
by gender. It is important to note the high
prevalence of smokers, regardless of gender. Across
all symptoms, participants reporting a symptom’s
presence had lower FEV1 than those not reporting
the same symptom (Table 2). Crude differences
between the presence and absence of each of the
symptoms were larger in males than females for
FEV1, but not for the FEV1/FVC ratio (Table 2).
Questions on wheezing/shortness of breath (Q101,
Q3, Q5) and on diagnosed asthma (Q1305, Q1306)
were associated with the largest reduction in lung
function and the greatest divergence between
genders.
All respiratory symptoms were found to be
associated with airways obstruction (Table 3). In
order to include all symptoms in a multivariate
model, factors combining symptoms were used.
The strongest association with airflow obstruction
was observed for the factor combining indicators of
diagnosed asthma, followed by the factor combin-
ing symptoms of wheezing/shortness of breath
(Table 3). The independent association of the
factor indicating the combination of symptoms of
wheezing/shortness of breath with the ratio FEV1/
FVC, after adjusting for the other factors, was
statistically significant and similar in both genders.
The fact that the strength of the odds ratios of the
factors on diagnosed asthma and wheezing/short-
ness of breath decreased after including them in
the same multivariate model is the result of a
residual correlation between the factors. However,
correlation between asthma and wheezing/short-
ness of breath could not explain an independent,
and statistically significant, association of each of
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Table 1 Characteristics of the population by
gender.
Male
(n¼ 6257)
Female
(n¼ 6284)
Mean age (years) 33.3 33.3
Mean height (m) 1.77 1.64
Smoking habits
Never (%) 41 46
Ex (%) 20 20
Current (%) 39 34
Atopy (specific
IgE40.35 KU/l) (%)
36 28
Bronchial
hyperesponsiveness
(%)
11 18
Mean FEV1 (ml) 4372 3233
Mean FVC (ml) 5364 3864
Mean ratio (FEV1/
FVC)*100
81.7 83.9
Distribution ratio
FEV1/FVC (%)
o70% 7 3
70–75% 12 7
X75% 81 90
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those factors with FEV1 in the multivariate model.
The factor combining symptoms associated with
chronic mucus hypersecretion was unrelated to
FEV1/FVCo70% after adjusting for other factors,
while there was still a significant association with
the factor indicating symptoms of cough in men.
When instead of using factors, all symptoms were
included in a multivariate model, only a few
symptoms remain in the final model due to its
strong multiple correlation. Hence, only wheezing
(Q1), chronic cough (Q7) and attacks of asthma
(Q1305) showed an adjusted significant association
with having a FEV1/FVCo70%, which provides a
coherent finding with the analysis with factors, but
loses part of the information provided by the
remaining symptoms, since the goodness of fit of
the model is lower. Heterogeneity among centres
was not significant (P40:4). Very similar results
were obtained when airways obstruction was
defined as FEV1/FVCo75%.
Among subjects with FEV1/FVCX70%, the factor
combining symptoms of wheezing/shortness of
breath showed the strongest association with FEV1
both in males and females, even after adjusting for
the factor representing diagnosed asthma (Table
4). Factors derived from questions on cough or
phlegm were not associated with FEV1 in the
multivariate model. Similar results were obtained
after excluding subjects with a FVC predicted
o100% or a FEV1 predicted o80%. The inclusion
of the factor combining symptoms of wheezing/
shortness of breath in the multivariate model
increased the goodness of fit of the model on
FEV1 by 3.4% in men, and 2.7% in women. This was
larger than the percent explained by smoking (in
pack years)Fat around 1%. The adjusted associa-
tion with the combination of questions referring to
wheezing/shortness of breath was quite homoge-
neous among countries (P for heterogeneity¼ 0.2)
(Fig. 1).
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Table 2 Mean FEV1 (in l) and FEV1/FVC (in %) by symptoms and gender.
Symptom FEV1 FEV1/FVC
Male Female Male Female
%n Yes No %n Yes No Yes No Yes No
Q1 23 4.15 4.43 23 3.12 3.26 79.3 82.4 82.1 84.4
Q101 11 4.06 4.40 13 3.09 3.25 78.3 82.1 81.6 84.2
Q102 15 4.13 4.41 14 3.08 3.26 78.8 82.2 81.6 84.2
Q2 13 4.16 4.40 14 3.10 3.25 80.1 81.9 82.4 84.1
Q3 5 4.07 4.38 8 3.07 3.25 78.6 81.9 82.5 84.0
Q4 20 4.15 4.42 23 3.11 3.27 80.2 82.1 83.1 84.1
Q5 6 4.00 4.39 6 3.02 3.25 78.8 81.9 81.6 84.0
Q6 24 4.24 4.41 36 3.20 3.25 80.8 82.0 83.4 84.1
Q7 14 4.14 4.40 13 3.13 3.25 80.2 81.9 83.0 84.0
Q8 15 4.24 4.39 16 3.16 3.25 80.5 81.9 82.6 84.1
Q801 9 4.15 4.39 9 3.08 3.25 79.9 81.9 81.7 84.1
Q9 16 4.17 4.40 12 3.14 3.25 80.7 81.9 82.9 84.0
Q10 12 4.14 4.40 9 3.16 3.24 80.2 81.9 82.3 84.0
Q1001 9 4.11 4.39 7 3.12 3.24 80.0 81.9 82.2 84.0
Q13 8 4.10 4.39 9 3.02 3.25 77.9 82.0 81.2 84.1
Q1301 7 4.06 4.39 8 3.00 3.25 77.8 82.0 80.8 84.1
Q1305 4 3.97 4.38 5 2.95 3.25 76.4 81.9 80.3 84.0
Q1306 3 3.87 4.38 4 2.83 3.25 74.6 81.9 78.4 84.1
Q1: Wheezing or whistling last 12 months (m); Q101: Breathless when wheezing; Q102: Wheezing or whistling due to a cold; Q2:
Woken up with tightness in chest, last 12m; Q3: Attack of shortness of breath at any time, last 12m; Q4: Attack of shortness of
breath after activity, last 12m; Q5: Woken up by an attack of shortness of breath, last 12m; Q6: Woken up by an attack of
coughing, last 12m; Q7: Usually cough first thing in the morning, last 12m; Q8: Usually cough during day or night in winter;
Q801: On most days as much as 3m per year; Q9: Usually bring up phlegm first thing morning, last 12m; Q10: Usually bring up
phlegm during day or night in winter; Q1001: On most days as much as 3m per year; Q13: Ever had asthma; Q1301: Confirmed by
a doctor; Q1305: Attack of asthma in the last 12m; Q1306: Currently taking medicines for asthma.
nPercent with symptoms.
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Table 5 and Fig. 1 show associations stratified by
a third variable (i.e., centre or smoking) in men and
women combined. This is intended to emphasize
the similarity of findings for the two genders and to
avoid small numbers when increasing strata.
Among subjects without airways obstruction, the
association between FEV1 and the factor related to
wheezing/shortness of breath was similar by smok-
ing, atopy and age (P for interaction40.35), and if
any, larger among those without smoking, without
atopy and older age (Table 5). However, the
association between the factor associated with
diagnosed asthma and FEV1 was only evident among
atopics and not among non-atopics (Po0:05).
Stratification by airway response to methacholine
eliminated any association between FEV1 in ob-
structed individuals and the factor associated with
diagnosed asthma. By contrast, the association
between the factor associated with diagnosed
asthma and airflow obstruction (FEV1/FVCo70%)
was not modified by any of these variables (P for
interaction 40.75) (data not shown).
Discussion
Reporting symptoms of asthma, and to a lesser
extent wheezing/shortness of breath, was asso-
ciated with airflow obstruction (ratio FEV1/
FVCo70%) in this young adult population. Among
subjects without airflow obstruction, reporting
symptoms of wheezing/shortness of breath was
associated with FEV1 levelsFindependent of asth-
ma, and in an invariant way according to smoking,
atopy, bronchial responsiveness and age. By con-
trast, symptoms of cough or hypersecretion were
not associated with lung function after considering
the symptoms of wheezing/shortness of breath and
asthma. These findings were very similar in both
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Table 3 Association (odds ratio, OR, and 95% confidence interval) between each of the symptoms or factors (n)
and ratio FEV1/FVC o70% by gender.
Symptom Univariate Multivariatew
Male Female Male Female
OR OR
Wheezing (W) 4.7 (3.6, 6.0) 3.9 (2.7, 5.54)
W and breathless 5.9 (4.4, 7.8) 4.9 (3.4, 7.07)
W out of cold 4.8 (3.7, 6.3) 4.2 (2.9, 6.08)
Tight chest 2.5 (1.9, 3.4) 4.0 (2.8, 5.68)
Short breath 3.7 (2.6, 5.4) 3.3 (2.1, 5.02)
After exercise 2.7 (2.1, 3.5) 3.1 (2.2, 4.48)
At night 4.6 (3.2, 6.6) 5.2 (3.4, 7.94)
Wheezing/short breathn 34.3 (21.4, 55.0)z 31.5 (17.7, 56.1)z 3.52 (1.53, 8.10)z 4.40 (1.45, 13.3)z
Cough at night 1.6 (1.2, 2.0) 1.3 (0.9, 1.87)
Cough morning 2.6 (1.9, 3.5) 1.7 (1.1, 2.64)
Cough winter 1.9 (1., 2.5) 2.2 (1.5, 3.25)
Chronic cough 2.4 (1.7, 3.4) 3.1 (2.1, 4.78)
Coughn 5.8 (3.8, 9.0)z 5.0 (2.8, 8.72)z 3.11 (1.54, 6.27)z 1.94 (0.76, 4.93)
Phlegm morning 1.7 (1.3, 2.3) 1.2 (0.8, 1.95)
Phlegm winter 1.9 (1.4, 2.6) 1.6 (1.03, 2.64)
Chronic phlegm 2.4 (1.7, 3.3) 1.6 (0.96, 2.77)
Hypersecretionn 2.8 (1.9, 4.2)z 2.0 (1.15, 3.55)z 0.55 (0.30, 1.01) 0.44 (0.18, 1.06)
Asthma ever 10.1 (7.4, 13.8) 8.8 (5.96, 12.9)
Attack asthma 10.6 (7.7, 14.7) 9.4 (6.37, 13.9)
Asthma diagnosed 14.5 (9.5, 22.1) 11.4 (7.23, 18.0)
Asthma treatment 27.4 (17.5, 43.0) 22.6 (14.2, 36.0)
Asthman 50.5 (30.6, 83.5)z 31.3 (18.7, 52.4)z 16.9 (7.82, 36.6)z 9.93 (4.01, 24.6)z
nFactor breathless/wheezing composed by questions Q1–Q5, factor cough by Q6–Q801, factor hypersecretion by Q9–Q1001 and
factor asthma by Q13–Q1306.
wAdjusted for all factors in the table and age, height, and centre.
zPo0:05 for factors. All symptoms had a univariate association with Po0:05:
Relations between respiratory symptoms and spirometric values 1029
genders, although the physiological differences in
the lung function, and among all countries, and
although the international differences in percep-
tion and report of symptoms including the word
asthma.14 It should be noted that the present study
refers to lung function level and not growth or
decline. Non-response in ECRHS seems unlikely to
bias present associations between symptoms and
lung function.19
The usefulness of this analysis in the clinical
setting to diagnose COPD at early stages is,
however, poor since the predictive value of
symptoms on lung function was weak. In the
epidemiological context, this study describes the
relations between respiratory symptoms and lung
function in the general population. The pathophy-
siological explanations of this agreement between
symptoms and lung function are unknown. The fact
that the association between the factor on wheez-
ing/shortness of breath and level of FEV1 was
similar in smokers and non-smokers and in atopic as
well as non-atopic subjects suggests that the
underlying causes of the respiratory damage could
not modify the association between these symp-
toms and lung function. Similarly, the remaining
association between wheezing and FEV1 after
stratifying for bronchial responsiveness, as well as
the lack of an effect modification, suggests the
presence of mechanisms other than bronchial
responsiveness. The fact that the association
between wheezing and FEV1 among subjects with-
out airflow obstruction was invariant after exclud-
ing subjects with abnormal FVC (o100% of the
predicted) indicates that these findings cannot be
attributed entirely to a low vital capacity.
Breathlessness is an important symptom in COPD.
Fletcher and Peto7 found that breathlessness was
the symptom most closely associated with loss of
lung function over time, and, ultimately, to a
negative prognosis. Whether or not breathlessness
presents as a consequence of loss of lung function is
not known with precision. Although the coexistence
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Table 4 Association between each of the symptoms or factors (n) and FEV1 (change in ml and standard error) by
gender, among subjects with an FEV1/FVCX70%.
Symptom Univariate Multivariatew
Male Female Male Female
Wheezing (W) 124 (16) 114 (12)
W and breathless 160 (22) 116 (15)
W out of cold 119 (19) 131 (15)
Tight chest 66 (20) 56 (20)
Short breath 124 (43) 91 (20)
After exercise 97 (19) 97 (12)
At night 114 (30) 73 (22)
Wheezing/short breathn 324 (37)z 261 (30)z -211 (58)z 169 (39)z
Cough at night 55 (15) 31 (10)
Cough morning 80 (20) 52 (15)
Cough winter 45 (19) 44 (14)
Chronic cough 72 (23) 72 (18)
Coughn 163 (30)z 121 (22)z 12 (47) 16 (32)
Phlegm morning 86 (23) 56 (15)
Phlegm winter 103 (24) 28 (17)
Chronic phlegm 101 (23) 55 (21)
Hypersecretionn 148 (30)z 82 (21)z 75 (45) 4 (28)
Asthma ever 142 (26) 137 (21)
Attack asthma 156 (27) 148 (23)
Asthma diagnosed 195 (39) 173 (32)
Asthma treatment 268 (50) 235 (33)
Asthman 318 (45)z 269 (39)z 139 (65)z 139 (47)z
nFactor breathless/wheezing composed by questions Q–Q5, factor cough by Q6–Q801, factor hypersecretion by Q9–Q1001 and
factor asthma by Q13–Q1306.
wAdjusted for all factors in the table and age, height and centre.
zPo0:05 for factors. All symptoms had a univariate association with Po0:05:
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of decreased FEV1 and dyspnea does show a wide
inter-individual variability8 and women reported it
more often (8%) than men (5%), we found a
homogeneous association in both genders and in
all centres among these young populations. This
suggests that the association appears in the early
stages of lung function decline, and does not seem
to be explained by the presence of diagnosed
asthma or bronchial hyper-reactivity, since it was
found after adjusting for both asthma and bronchial
hyper-reactivity. Therefore, breathlessness (with
or without wheezing) in young subjects should be
regarded as a symptom associated with poor lung
function, and probably indicates an early effect of
a disease that will appear more clearly later in life.
We also found an association between chronic
cough and mucus hypersecretion, which disap-
peared after adjusting for symptoms of wheezing/
shortness of breath. This likely indicates that the
association with chronic cough and hyperesecretion
is due in large measure to a third variable such as
symptoms of wheezing/shortness of breath. We
confirmed this finding after using orthogonal
factors (i.e., statistical modification of factors to
avoid any correlation among them when used in the
same multivariate model, data not shown). As a
consequence, these results reinforce the extended
belief that chronic cough and expectoration at a
young age are minor disorders without any relevant
impact on health status. Fletcher et al.1 concluded
that mucus hypersecretion and decreased FEV1
were different entities, which agree with other
studies.2–4 However, some studies5–6 have found an
association between mucus hypersecretion and
both decline in FEV1 and hospital admissions
because of COPD, perhaps because these studies
incorporated older people or did not adjust for
other symptoms.
Among young adults in this study, asthma showed
the strongest negative association with airflow
obstruction. This could potentially be explained
as a result of not including a bronchodilator test in
the study, except that all subjects were studied at
baseline levels. In addition, there is evidence that
asthmatics have a fixed deficit in FEV1
12Falthough
debate continues about whether or not asthmatics
have a slower growth and a more rapid decline than
non-asthmatics.20,21 When the results of subjects
without airflow obstruction were stratified by a
third variable, we found that the association
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Figure 1 Change in FEV1 (in litres) and 95% confidence interval in relation to the factor combining symptoms of
wheezing/shortness of breath among those without airways obstruction, after adjusting for age, sex, height and the
factors combining symptoms of asthma, cough and hypersecretion.
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between asthma and lung function was only present
among those subjects with atopy, not among non-
atopic subjects. However, an association was found
between the factor on asthma and having a FEV1/
FVCo70%, both among atopic and non-atopic
subjects. This discrepancy between the association
with the ratio FEV1/FVCo70% and changes in FEV1
among subjects without airflow obstruction merits
confirmation in longitudinal studies assessing lung
function growth and decline, and may signal a more
moderate impact of asthma on non-reversible lung
function impairment among non-atopic asthmatics.
Despite the fact that previous studies suggest that
the effects of asthma on lung function growth vary
by gender,22,23 we found, in general, a lack of
difference between the genders in terms of the
associations resulting from a lower FEV1. Only in
the case of a FEV1/FVC ratio o70% did we observe
a stronger association in men than women for the
factor indicators of diagnosed asthmaFand even
then the differences were not statistically signifi-
cant. This may suggest that the finding of a lack of
differences by sex in the association of the factor
combining symptoms of wheezing/shortness of
breath and airways obstruction could be more
closely related to a differential use of the term
‘asthma’ as a diagnostic label than to a true
difference between genders.
After excluding subjects with airflow obstruc-
tion, symptoms of wheezing and/or shortness of
breath, which were highly prevalent despite the
young age of the study participants, showed the
strongest association with lower levels of lung
function. The international homogeneity of this
finding strengthens its validity. Underlying mechan-
isms of this association are unknown, as is its
potential reversibility. Ultimately, however, these
findings are useful for studies on respiratory
damage of environmental causes because they
suggest that symptoms of wheezing/shortness of
breath are the best indicator of lung function
impairment and could be used in general popula-
tion studies to operatively define COPD at early
stages.
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